Acadian Asset Management LLC Acquires 115,527 Shares of Phreesia, Inc. $PHR

Key Points

• Acadian Asset Management LLC increased its stake in Phreesia, Inc. by 105.2%, owning 225,317 shares valued at approximately $5.75 million as of the latest SEC filing.
• Hedge funds and institutional investors now own about 92.10% of Phreesia's stock, indicating strong interest and investment confidence in the company.
• Phreesia recently reported better-than-expected quarterly earnings, with $117.26 million in revenue and earnings per share of $0.01, surpassing analysts' estimates.

Acadian Asset Management LLC boosted its stake in shares of Phreesia, Inc. (NYSE:PHR - Free Report) by 105.2% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 225,317 shares of the company's stock after buying an additional 115,527 shares during the period. Acadian Asset Management LLC owned approximately 0.38% of Phreesia worth $5,754,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC bought a new position in Phreesia during the 1st quarter valued at approximately $774,000. Principal Financial Group Inc. bought a new position in Phreesia during the 1st quarter valued at approximately $1,623,000. Deutsche Bank AG increased its position in Phreesia by 95.9% during the 4th quarter. Deutsche Bank AG now owns 57,297 shares of the company's stock valued at $1,442,000 after buying an additional 28,047 shares in the last quarter. Bessemer Group Inc. increased its position in Phreesia by 23.2% during the 1st quarter. Bessemer Group Inc. now owns 47,758 shares of the company's stock valued at $1,222,000 after buying an additional 8,978 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in Phreesia during the 1st quarter valued at approximately $462,000. Institutional investors own 92.10% of the company's stock.

Insider Buying and Selling at Phreesia

In other news, SVP Amy Beth Vanduyn sold 1,762 shares of the business's stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $23.28, for a total transaction of $41,019.36. Following the completion of the sale, the senior vice president owned 112,479 shares of the company's stock, valued at $2,618,511.12. The trade was a 1.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider David Linetsky sold 1,064 shares of the business's stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $23.50, for a total transaction of $25,004.00. Following the sale, the insider directly owned 173,888 shares of the company's stock, valued at approximately $4,086,368. The trade was a 0.61% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 128,250 shares of company stock worth $3,737,117. 5.50% of the stock is owned by corporate insiders.

Phreesia Stock Performance

PHR traded up $1.00 during mid-day trading on Thursday, reaching $24.28. 801,987 shares of the company traded hands, compared to its average volume of 1,182,744. The stock has a market capitalization of $1.45 billion, a P/E ratio of -57.81 and a beta of 0.72. The company has a quick ratio of 2.12, a current ratio of 2.12 and a debt-to-equity ratio of 0.02. The company's fifty day moving average price is $27.62 and its 200-day moving average price is $26.39. Phreesia, Inc. has a 52-week low of $17.07 and a 52-week high of $32.76.

Phreesia (NYSE:PHR - Get Free Report) last announced its earnings results on Thursday, September 4th. The company reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.08. The business had revenue of $117.26 million during the quarter, compared to analyst estimates of $116.39 million. Phreesia had a negative net margin of 5.35% and a negative return on equity of 8.75%. The company's quarterly revenue was up 14.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.03) EPS. Phreesia has set its FY 2026 guidance at EPS. On average, sell-side analysts expect that Phreesia, Inc. will post -1.1 EPS for the current year.

Wall Street Analyst Weigh In

PHR has been the subject of a number of recent analyst reports. Piper Sandler boosted their price objective on shares of Phreesia from $33.00 to $34.00 and gave the stock an "overweight" rating in a report on Friday, September 5th. KeyCorp boosted their price objective on shares of Phreesia from $28.00 to $35.00 and gave the stock an "overweight" rating in a report on Monday, July 14th. Stephens restated an "overweight" rating and issued a $32.00 price objective on shares of Phreesia in a report on Wednesday, September 3rd. Truist Financial boosted their price objective on shares of Phreesia from $35.00 to $36.00 and gave the stock a "buy" rating in a report on Friday, September 5th. Finally, DA Davidson upgraded shares of Phreesia to a "strong-buy" rating in a report on Monday, September 8th. One research analyst has rated the stock with a Strong Buy rating and twelve have given a Buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $34.08.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.